CETP inhibition Reduces Cardiovascular Events by 1 Lowering of Cumulative LDL Exposure: Reconciling 2 **Evidence from Human Genetics and Clinical Trials** 3

4 5

6

Fredrik Landfors^{1,2,*}, John J.P. Kastelein^{3,4}, Elin Chorell¹

- 7 ¹ Department of Public Health and Clinical Medicine, Section of Medicine, Umea
- 8 University, S-901 87 Umea, Sweden.
- 9 ² Lipigon Pharmaceuticals AB, S-907 36 Umea, Sweden.
- ³ Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, 10
- 11 the Netherlands
- 12 ⁴ NewAmsterdam Pharma, Naarden, the Netherlands
- 13
- 14 * To whom correspondence should be addressed.
- 15
- 16 Contact information for the corresponding author: Fredrik Landfors, Department of
- Public Health and Clinical Medicine, Umea University, S-901 87 Umea, Sweden; Email: 17
- 18 Fredrik.Landfors@umu.se; Phone: +46 (0) 70-454 92 08.

19 Abstract

20 **Background:** Genetic studies consistently demonstrate that individuals born 21 with reduced Cholesteryl Ester Transfer Protein (CETP) activity experience lower rates of 22 atherosclerotic vascular disease throughout their lives. In contrast, short-term 23 randomized controlled trials of CETP inhibitors have yielded mixed results, with only one 24 of four trials reporting a reduction in clinical events. Several theories have been proposed 25 to explain this discrepancy, but none fully account for the central mechanism of 26 atherosclerosis: the cumulative lifetime exposure to circulating low-density lipoprotein 27 (LDL) particles in the arterial walls.

Objectives: We aimed to reconcile these conflicting findings by examining
 the relationship between cumulative LDL exposure and atherosclerosis risk across both
 genetic studies and clinical trials.

31 **Methods:** We analyzed 679 carriers of *CETP* protein-truncating variants 32 (resulting in reduced or non-functional CETP protein) and 505,837 non-carriers in a 33 population with 95,568 atherosclerosis events. Additionally, we assessed treatment 34 effects relative to cumulative LDL reductions in 34 cardiovascular prevention trials 35 involving 328,036 participants and 53,161 events.

36 **Results:** Heterozygous *CETP* protein-truncating variant carrier status 37 reduced atherosclerotic disease risk (odds ratio, 0.70; 95% confidence interval, 0.57-38 0.85; $P=5\times10^{-4}$). In clinical trials, we observed a significant interaction between the magnitude and duration of LDL lowering on treatment effects (hazard ratio, 0.69 per 10-39 40 mmol/L×years; 95% confidence interval, 0.52–0.90; P=0.007), supporting that reducing 41 cumulative LDL exposure is key to lowering cardiovascular risk. When comparing 42 genetics with trial outcomes, accounting for differences in timing, duration, and follow-43 up, we observed consistent effects on atherosclerosis-related events per LDL years across genetic and pharmacological CETP inhibition, as well as with statins, ezetimibe, 44 45 PCSK9 inhibitors, and familial hypercholesterolemia-associated variants (hazard ratio, 46 0.74 and 0.69 per 10-mmol/L×years, respectively). This suggests that CETP inhibition 47 reduces cardiovascular risk primarily through LDL. Notably, several trials failed to achieve 48 sufficient cumulative LDL reduction to impact clinical events, and this was not unique to 49 CETP inhibitors.

50 **Conclusion:** Our findings indicate that future CETP inhibitor trials achieving 51 substantial and sustained LDL reduction will demonstrate efficacy in preventing 52 cardiovascular events. These results highlight the importance of long-term LDL lowering 53 and support further investigation of CETP inhibition as a strategy for cardiovascular 54 prevention.

56 Introduction

57 Cholesteryl ester transfer protein (CETP) is a lipid exchange protein found in the circulation of humans and certain higher mammals. It facilitates the transfer of 58 cholesteryl esters from high-density lipoprotein (HDL) to low-density (LDL) or very-low-59 60 density lipoprotein (VLDL) in exchange for triglycerides^{1,2} Reduced CETP activity may benefit human health by shifting plasma cholesterol from atherogenic LDL and VLDL to 61 62 HDL, decreasing the number of cholesterol-containing particles that can accumulate in arterial walls, potentially slowing down atherosclerosis development.³⁻⁵ Several studies 63 also suggest CETP inhibition improves HDL functionality and promotes cholesterol efflux 64 from plaque macrophages, further mitigating atherogenesis.^{3,6,7} However, the precise 65 impact of CETP inhibition on atherosclerosis remains under investigation. 66

67 CETP's contribution to atherogenesis led to the development of CETP inhibitors for atherosclerotic cardiovascular disease (ASCVD). Clinical trials of these 68 inhibitors, however, yielded mixed results. Torcetrapib, the first inhibitor, increased 69 70 cardiovascular events and mortality through off-target effects such as raised blood pressure and aldosterone levels.^{8,9} Subsequent inhibitors, dalcetrapib and evacetrapib, 71 72 were safe but failed to reduce cardiovascular events in outcomes trials, possibly due to insufficient LDL lowering and the short duration of the trials.¹⁰⁻¹² Anacetrapib showed 73 74 promise by reducing ASCVD events in a phase 3 trial, but its development was halted after it was found to accumulate in adipose tissue, raising long-term safety concerns.^{13,14} 75 Obicetrapib, a less lipophilic yet potent CETP inhibitor, is currently being evaluated in 76 77 phase 3 trials.^{10,15} The single success among four major trials has cast doubt on CETP 78 inhibition's therapeutic value in atherosclerosis prevention.

79 Early atherosclerotic lesions begin forming in childhood, and cumulative 80 exposure to LDL drives the progression of ASCVD through plaque formation.^{16,17} 81 Therefore, evaluating the long-term effects of CETP inhibition requires considering the 82 duration and timing of LDL cholesterol (LDL-C) lowering. Human genetics offers a way to 83 assess the potential of such sustained CETP inhibition in preventing ASCVD. Genetic 84 variants that naturally reduce CETP activity from conception provide a "natural experiment" to predict the long-term effects of CETP inhibition. By analyzing health 85 86 outcomes in individuals carrying protein-truncating variants (PTVs) in the CETP gene,

which lead to reduced or non-functional proteins, we can infer the impact of lifelong CETP
inhibition on ASCVD risk.¹⁸⁻²¹ This approach minimizes confounding and reverse
causation, and has proven effective in predicting drug target outcomes.^{22,23}

90 Given the potential of CETP inhibition and the conflicting results from clinical 91 trials, this study aimed to determine whether CETP inhibition reduces ASCVD risk by lowering LDL particles. To ensure reliable long-term estimates, we analyzed the effects of 92 93 genetic CETP inhibition across diverse populations. Additionally, we tested the 94 cumulative LDL exposure hypothesis using clinical trial data. To reconcile the conflicting 95 findings on CETP inhibition, we introduce the concept of 'LDL-C Plaque Years,' which models the cumulative impact of LDL-C reduction over time. This enabled a direct 96 97 comparison between lifelong genetic reductions and shorter-term pharmacological effects from clinical trials. By accounting for differences in timing, duration, and 98 99 magnitude between genetic and clinical studies, we found that CETP inhibition lowers ASCVD risk, but only when LDL-C is significantly reduced for a sustained period. 100

101 Methods

The analyses in this paper were conducted in two sequential steps. First, we measured the impact of *CETP* PTVs on ASCVD risk in the UK Biobank and performed a meta-analysis across diverse ancestries. Second, we assessed the plausibility of these genetic results by comparing the effects of genetic and pharmacological CETP inhibition on ASCVD risk relative to their cumulative LDL-C lowering, and against guideline-recommended lipidlowering therapies and *LDLR* PTVs (encoding the LDL receptor).

108 Step 1

109 Genetic association study of *CETP* protein-truncating variants and

110 atherosclerotic disease

111 Study design and data sources

112 The impact of lifetime CETP inhibition on ASCVD risk was measured in CETP 113 PTV carriers and non-carriers in the United Kingdom Biobank (UKB). The UKB is a 114 population-based study that has gathered a vast array of research data, including health outcomes data, genetics, and blood chemistry from 500,000 participants across the 115 116 United Kingdom.²⁴ The study enrolled individuals aged 40-69 between 2006 and 2010, during which blood samples were collected. Ongoing follow-up of these participants 117 118 ensures that their health information is continuously updated through medical records, 119 death certificates, and registries. The data (UKB v18.1) were released to us on January 14, 120 2024.

121 The primary outcome was ASCVD events (TABLE 1 details the primary and 122 secondary endpoints). Diagnoses and event dates were retrieved from the first 123 occurrences data set (UKB data fields 131271–131423). ASCVD events were defined as 124 the first occurring hospital-record, death certificate, or primary care diagnosis of 125 coronary heart disease (ICD-10: I20-I25), ischemic stroke (I63), or peripheral 126 atherosclerosis (170). We did not consider self-reported diagnoses as being positive for 127 an endpoint. Myocardial infarction was defined as being positive for ICD-10 codes I21-128 123. Cardiovascular death was defined as any atherosclerotic event (defined above) or sudden cardiac death (I46.1) being recorded as the primary cause of the death in a death 129

certificate (UKB data field 40001). Major adverse cardiovascular events were defined as
the first-occurring stroke, myocardial infarction, or cardiovascular death.

132 Exposure to a defective CETP allele was assumed to begin at conception, 133 and participants were followed from their birth (UKB data fields 34, 54) until the 134 occurrence of the first event, loss to follow-up (UKB data field 191), death (UKB data field 135 40000), or the end of the study period (January 1, 2023), whichever occurred first. 136 Diabetes presence, statin medication, and smoking status were defined according to 137 their self-reported status at enrollment between the years 2006-2010 (UKB data fields 138 2443, 20003, 20116). LDL-C was measured both directly (UKB data field 30780), and calculated using the Friedewald formula from total cholesterol, HDL, and triglycerides 139 140 (UKB data fields 30690, 30760, 30870). Non-HDL cholesterol was calculated by 141 subtracting HDL from total cholesterol, and remnant cholesterol was calculated by subtracting directly measured LDL-C cholesterol from non-HDL cholesterol. 142 143 Apolipoprotein A1, Β, and Lipoprotein(a) levels were measured using 144 immunoturbidimetry (UKB data fields 30630, 30640, 30790). Diastolic and systolic blood pressure was measured at recruitment using automated monitors (UKB data fields 4079, 145 146 4080). The proportion of missing observations for each measure is presented in TABLE 1. 147 Missing observations were not imputed.

148

149 Pre-processing and quality control of genetic data

150 To measure CETP PTV carrier status, we used the UK Biobank exome sequencing data (UKB data field 23157).²⁵ Population variant call file meta data were 151 152 annotated using gnomAD v.4.1.0, and Ensembl Variant Effect Predictor v. 111 (VEP).^{21,26} 153 Variants qualified as PTVs if their impact on the MANE transcript (Matched Annotation 154 from NCBI [National Center for Biotechnology Information] and EBI [European 155 Bioinformatics Institute]) were annotated with VEP consequences "frameshift variant", 156 "splice acceptor variant", "splice donor variant", "start lost", "stop gained", or "stop lost", 157 and their allele frequency was <0.001. To prevent batch effect bias, we excluded variants 158 with a genotype depth of coverage (DP) ≤ 10 or were missing in more than 90% of the population. For single nucleotide variants, we further filtered out those with a DP <10, 159 160 genotype quality (GQ) <20, and a binomial test of the alternate alleles deviation from the

161 heterozygous expectation of 0.5 with a P-value $<1 \times 10^{-3}$. For insertions and deletions, we 162 removed variants with DP <10 and GQ <20. Details on the 60 different CETP PTVs found in 163 the UK Biobank trans-ancestry exome sequencing sample are provided in SUPPLEMENTAL 164 TABLE 1. In a sensitivity analysis, we assessed the impact of PTV loss-of-function 165 classification using LOFTEE (Loss-Of-Function Transcript Effect Estimator).²⁷ We found no differences in the association between CETP PTV carrier status and HDL levels across 166 167 high-confidence, low-confidence, or not classified PTVs, indicating that LOFTEE 168 classifications were not relevant to CETP PTVs (SUPPLEMENTAL FIGURE 1).

169

170 Genetic association studies

171 The inferential validity of genetic association studies relies on the 172 assumption that the genetic variants under investigation are distributed in a random-like 173 pattern within the study population. This randomness typically occurs because 174 transmission of alleles from parents to offspring, or the emergence of de novo variants, is 175 a random-like natural process that mimics randomization in a clinical trial. Potential 176 confounders, such as population stratification, assortative mating, or relatedness, could 177 however impact the CETP PTV-ASCVD association by misbalancing the distribution of 178 non-lipid risk factors between variant carriers and non-carriers.²⁸⁻³⁰ This would be 179 analogous to failure of randomization in a clinical trial. To examine if such sources of bias 180 were present, we tested whether the distribution of non-lipid ASCVD risk factors were 181 similar in CETP PTV carriers and non-carriers. P values and 95% confidence intervals 182 were computed using t-tests for continuous variables and Fisher's exact test for 183 categorical variables (see TABLE 1).

184 In the analysis of the primary endpoint, the association between CETP PTV 185 carrier status and ASCVD was measured using Cox regression, adjusting for age, sex, and 186 the six first genetic principal components (UKB data field 22009). We restricted the 187 sample to European ancestry individuals to limit bias from population stratification. To 188 control for excessive relatedness, only one individual from each group of individuals more 189 closely related than third-degree relatives was selected for further analyses, based on a KING coefficient cut-off of 0.0884.³¹ To reduce genotyping error, we excluded samples 190 that were outliers for heterozygosity (principal components-adjusted heterozygosity 191

>0.1903) or had a missing rate >5%. We also excluded participants with sex chromosome
aneuploidies (UKB data field 22019).

194 A trans-ancestry meta-analysis was conducted to determine if the 195 inferences were valid across ancestries. We included a previous study of Nomura et al., 196 to increase statistical power (80,001 individuals and 44% East Asian, 44% European, 12% 197 South Asian ancestry).³² Compared to the ASCVD composite endpoint used in the UK 198 Biobank analyses, the outcome in the Nomura et al. paper was restricted to coronary 199 heart disease alone. However, both endpoints reflect the same underlying 200 pathophysiological phenotype, atherosclerosis, which justifies their inclusion in the 201 meta-analysis. The odds ratio of ASCVD between CETP PTV carriers versus non-carriers 202 was measured in 6908; 409,638; and 6969 UK Biobank participants of African, European, 203 and South Asian ancestry, respectively. To harmonize the unit of effect measurements 204 between the studies, we applied logistic regression with Firth's correction in the UK 205 Biobank subset, while otherwise reusing the analysis strategy described in the previous 206 section.³³ Meta-analysis was conducted using a fixed-effects inverse variance weighted 207 estimator. Study heterogeneity was estimated using Cochran's Q test and calculating the 208 *l*² statistic.

209 Step 2

210 Cumulative LDL cholesterol exposure and atherosclerotic cardiovascular

211 disease risk in genetic studies and clinical trials

212 Selection of clinical trials and genetic exposures

213 A list of clinical trials was retrieved from previous systematic reviews of 214 guidelines-recommended lipid-lowering therapies for ASCVD prevention (see SUPPLEMENTAL TABLE 2 for details).³⁴⁻³⁶ We then added trials involving dialysis and heart 215 216 failure patients, one post-acute coronary syndrome trial, and the pitavastatin trials.³⁷⁻⁴² 217 The guideline-recommended therapies were statins, ezetimibe, and PCSK9 inhibitors. To 218 obtain precise and unbiased effect estimates, we applied specific selection criteria. First, 219 each trial was required to be designed to measure cardiovascular outcomes as the 220 primary outcome and have recorded more than 100 events. Second, trials that were 221 stopped early due to efficacy were excluded if the information fraction was less than 0.90,

222 as truncated trials tend to overestimate treatment effects, especially when the event rate 223 is low.⁴³ This overestimation is sometimes referred to as the "winner's curse". The 224 information fraction was calculated as the ratio of the pre-specified planned events to the 225 actual observed events before termination. Third, to ensure comparability between 226 studies, the effect had to be measured using the hazard ratio (HR) or incidence rate ratio 227 (IRR). The inclusion of studies using IRR for measuring the primary outcome was justified 228 since, in most cases, the IRR closely resembles the HR.⁴⁴ We performed sensitivity 229 analyses to assess the impact of the second selection criteria (see SUPPLEMENTAL FIGURES 230 **2-5**). Additionally, we examined whether excluding non-double-blind trials affected the 231 results (SUPPLEMENTAL FIGURES 6-7).

From each study, we extracted the reported composite outcome most closely resembling the ASCVD composite endpoint described in **STEP 1**. LDL-C reduction from treatment was obtained from the text, or if unavailable, directly from figures using a web-based tool (see **DATA AVAILABILITY**). Other key variables, such as baseline age and baseline LDL-C cholesterol, were extracted from tables, text, or supplemental materials. Regarding CETP inhibitors, we excluded torcetrapib from the meta-analysis due to its offtarget toxicity.

239 As a genetic positive control, we assessed the effect of lifetime LDLR PTV 240 carrier status (encoding the LDL receptor) on ASCVD risk in the UK Biobank. Carrying an LDLR PTV typically meets the genetic diagnostic criteria for heterozygous familial 241 242 hypercholesterolemia, a condition characterized by increased lifetime LDL-C exposure 243 that profoundly impacts ASCVD risk.⁴⁵ Given the focus on the impact of cumulative LDL-244 C differences on ASCVD, the LDLR PTV carriers served as a relevant genetic comparator 245 to CETP PTV carriers. The association between LDLR PTV carrier status and ASCVD risk 246 was measured using the same methods as described in the CETP PTV analyses in STEP 1. 247 Additional details on the UK Biobank LDLR PTVs are provided in **SUPPLEMENTAL TABLE 3**. 248 The conditional effect of CETP and LDLR PTVs on LDL-C were measured using linear 249 regression adjusting for age, sex, and the six first genetic principal components.

250 LDL cholesterol exposure trajectories and calculation of cumulative LDL cholesterol

251 *difference*

Low-density lipoprotein levels are low at birth, rise with age, and stabilize in 252 253 late middle age.^{17,46,47} Consequently, lifetime ASCVD risk attributable to LDL-C is a time-254 varying exposure that needs accounting for to accurately estimate its impact.⁴⁸⁻⁵⁰ For each intervention or genetic exposure, we quantified the reduction in cumulative LDL-C 255 256 exposure, expressed as "LDL-C Plaque Years Difference", by integrating over population 257 mean LDL-C life course trajectories (see FIGURE 1). First, we adjusted the standard 258 population LDL-C trajectory to match the baseline LDL-C levels of each specific study 259 population. This adjustment was done by scaling the mean LDL-C trajectory using the 260 ratio of the study's baseline LDL-C level to a general population reference mean LDL-C value (3.55594 mmol/L), accounting for differences in baseline LDL-C levels between 261 262 population-based studies and clinical trials involving secondary or high-risk prevention 263 populations. The LDL-C trajectories were extracted from references,^{17,46,47} and the exact 264 population trajectories that were used are provided in **SUPPLEMENTAL TABLE 4**.

265 Then, we calculated the area under the LDL-C versus age curve (AUC) from 266 the start of follow-up to the end (defined as the start age plus the median time of follow-267 up) to represent cumulative LDL-C exposure without intervention. To model the effect of 268 the intervention (or genetic exposure), we adjusted the LDL-C trajectory according to the 269 intervention's reported effect size. Our approach assumed a time-independent relative 270 lowering of LDL-C levels across the exposure-time trajectory. To reflect this constant 271 relative reduction of LDL-C over time, we applied a scaling factor k = 1 + 1LDL-C Effect 272 across the intervention or genetic exposure trajectory. We then LDL-C Baseline Mean 273 recalculated the AUC for the adjusted LDL-C trajectory, representing cumulative LDL-C 274 exposure with the intervention (or genetic exposure). The difference between the two 275 AUCs (without and with intervention) therefore reflected the total reduction in cumulative 276 LDL-C exposure due to the intervention (or genetic exposure). These differences were 277 computed for each study and recorded as the "LDL-C Plaque Years Difference". The 278 measure allowed us to compare how much cumulative LDL-C exposure was lowered in 279 each clinical trial or genetic association study. Reproducible code for these calculations 280 is provided in the **SUPPLEMENTAL NOTE**.

281 Meta-analysis of genetic and pharmacological cumulative LDL cholesterol lowering and 282 atherosclerotic disease risk

To compare CETP inhibition with the guidelines-recommended lipidlowering therapies and *LDLR* PTVs, we conducted separate analyses for CETP and the other approaches to measure the association between cumulative LDL-C differences and ASCVD risk. We used a fixed-effects inverse variance-weighted estimator to measure the combined effect size across studies. Study heterogeneity was assessed using Cochran's Q test and the l^2 statistic. Leave-one-out sensitivity analyses of effect size and heterogeneity are presented in **SUPPLEMENTAL FIGURE 8**.

290 We performed additional sensitivity analyses because, if atherosclerosis 291 follows a cumulative exposure model, both the magnitude and duration of LDL exposure 292 (LDL-C × follow-up length) should approximately predict the observed risk reductions. We 293 used multiple meta-regression to assess the impact of LDL-C lowering and mean or 294 median follow-up duration on the ASCVD hazard reduction observed in clinical trials. The 295 data were fitted with a linear random-effects mixed model, and restricted maximum 296 likelihood estimated heterogeneity. P values were validated using permutation tests.⁵¹ We 297 performed sensitivity analyses by adjusting the interaction term (LDL-C × median time of 298 follow-up) for baseline LDL-C, annual and cumulative event risk, age at enrollment, and 299 year of publication, and used multilevel inference to rank them as predictors 300 (SUPPLEMENTAL FIGURE 10).

301 Ethical review and reporting of statistical tests

302 This research has been conducted using the UK Biobank Resource under 303 Application Number 148828. The LDL-C trajectory and meta-analyses used publicly 304 available summary data that did not require separate ethical review. The research 305 adhered to the ethical standards set forth in the Declaration of Helsinki. The primary 306 research question in this study was to measure the impact of long-term CETP inhibition 307 on ASCVD risk. The other statistical tests in **STEP 1** were considered secondary endpoints. 308 STEP 1 and STEP 2 analyses were separate, and did not require correcting for a family-wise 309 error rate. Consequently, P values and 95% confidence intervals reported in this paper 310 are presented without correction for multiple comparisons.

312 Results

313 Step 1

314 Protein-truncating variants that inhibit CETP throughout life reduce the risk

315 of atherosclerotic disease

316 Descriptive characteristics on the 409,638 European-ancestry individuals 317 meeting inclusion criteria are presented in **TABLE 1**. The mean age at recruitment into the 318 UK Biobank between 2006-2010 was 56.8 years and 53.9% were female. Genetic 319 exposures begin at conception, and the median time of birth to end of follow-up was 70.2 320 years. Between 1958 and 2023 (median year 2013, interguartile range 2006–2018); 61,091 321 first occurrences of ASCVD were recorded. Details on the composite endpoints are 322 provided in the METHODS section and FIGURE 2. UK Biobank CETP PTV variant types and 323 allele frequencies are listed in **SUPPLEMENTAL TABLE 1**.

324 There were 385 European-ancestry CETP PTV carriers available for analysis 325 in the UKB. As anticipated, they presented with elevated HDL cholesterol (+0.42 mmol/L, 326 $P=9\times10^{-37}$), and lowered LDL cholesterol (-0.18 mmol/L, $P=3\times10^{-5}$). Apolipoprotein A1 and 327 Apolipoprotein B differed according to a similar pattern (**TABLE 1**). Lipoprotein(a) levels 328 were lower in CETP PTV carriers (-6.5 nmol/L, P=0.021). Statin treatment was less 329 common in CETP PTV carriers (16.3% vs. 12.5%, P=0.039). This was expected, as lowered 330 LDL-C from birth should influence a physician's decision to prescribe statins later in life. 331 Non-lipid risk factors and participant characteristics were well-balanced between CETP 332 PTV carriers and controls (TABLE 1). The only exception was diastolic blood pressure, 333 which was 1.3 mmHg higher in CETP PTV carriers (P=0.043). It is unclear whether this 334 difference reflects a true effect or was due to multiple comparisons, as previous trials with dalcetrapib, evacetrapib, anacetrapib, and obicetrapib did not report elevations in 335 diastolic blood pressure.^{11-13,52} Overall, these data suggests that the allocation to CETP 336 337 PTVs occurred in a random-like manner, making it unlikely that imbalances in ASCVD risk 338 factors influenced the results.

Lifetime CETP inhibition from a *CETP* PTV reduced absolute ASCVD risk by
4.8 percentage points (TABLE 1). The adjusted hazard ratio was 0.65 (95% confidence
interval, 0.48–0.90, *P* value = 0.008). This risk reduction corresponded to an average gain

of 1.1 years in ASCVD event-free survival before the age of 80 (FIGURE 2A). Although the
secondary endpoints had overlapping CIs and were not statistically distinguishable, the
association between *CETP* PTVs and the composite ASCVD endpoint seemed to be
primarily driven by coronary heart disease and ischemic stroke events (FIGURE 2B).
Notably, *CETP* PTV carrier status did not significantly affect all-cause mortality but
reduced the risk of a composite endpoint of ASCVD or all-cause death (FIGURE 2B).

348 The trans-ancestry meta-analysis included 506,516 individuals: 6908 of 349 African; 36,856 of East Asian; 446,157 of European; and 16,595 of South Asian ancestry. 350 Among them, 679 were CETP PTV carriers. There were 95,568 ASCVD cases and 410,948 controls. Between-study heterogeneity was low (Q = 3.39, P value = 0.34, l^2 = 11.5%). 351 352 Lifetime CETP inhibition was associated with a reduced ASCVD risk, with an odds ratio of 0.70 (95% confidence interval, 0.57–0.85, meta-analysis P value = 4.7×10^{-4}) (Figure 2C). 353 354 Taken together, these results indicate that lifetime CETP inhibition significantly reduces 355 ASCVD risk, with no evidence of this effect being dependent on genetic ancestry.

356 Step 2

357 CETP inhibition reduces atherosclerotic disease risk by lowering LDL

Data on ASCVD risk reduction, baseline LDL-C, LDL-C lowering, age, and median or mean time of follow-up were extracted from 47 clinical trials of CETP inhibitors, statins, ezetimibe, and PCSK9 inhibitors. Four trials were excluded because they were not designed to assess treatment effects on clinical cardiovascular endpoints. Eight trials terminated early for efficacy were excluded to prevent inflated effect estimates due to the "winner's curse". One trial was excluded for not reporting outcomes as hazard ratios or incidence rate ratios, making it incomparable to the other trials.

The remaining 34 cardiovascular outcomes trials covered a population of 365 328,036 individuals with 53,161 ASCVD events across both primary and secondary 367 prevention settings. Three trials studied CETP inhibitors (n_{total} =58,412; n_{events} =7126), 23 368 trials evaluated statins (n_{total} =160,910; n_{events} =31,854), three examined ezetimibe 369 monotherapy (n_{total} =23,645; n_{events} =6271), two were of ezetimibe/statin combination 370 therapy (n_{total} =11,143; n_{events} =1480), and three investigated PCSK9 inhibitors (n_{total} =73,926; 371 n_{events} =6430). Age at enrollment ranged from 49.8 to 75.4 years, with follow-up durations

between 0.3 and 6.7 years. Baseline LDL-C ranged from 1.58 to 4.97 mmol/L, with reductions between 0.03 and 1.80 mmol/L. Twenty-nine trials were double-blind, and five were not. Further details, including study settings and extracted endpoints, are provided in **SUPPLEMENTAL TABLE 2**.

376 To determine whether the clinical trial data aligned with the cumulative LDL 377 exposure hypothesis of atherosclerosis, we used multiple meta-regression to assess the 378 impact of LDL-C lowering magnitude and duration on ASCVD risk. We identified a 379 significant interaction between LDL-C reduction and time of follow-up (P = 0.007) (see 380 FIGURE 3). Sensitivity analyses confirmed the robustness of this association 381 (SUPPLEMENTAL FIGURES 9-10). These data support the hypothesis that LDL-C's effect on 382 ASCVD risk follows a cumulative exposure model and provide a theoretical basis for 383 modeling genetic effects alongside clinical trial data, as described next.

384 We compared genetic and pharmacological CETP inhibition with guideline-385 recommended lipid-lowering therapies and LDLR PTVs to evaluate their effects on ASCVD 386 relative to cumulative LDL-C lowering. We found that the predicted effect of CETP 387 inhibition was similar to the combined estimate from statins, PCSK9 inhibitors, ezetimibe, 388 and LDLR PTVs (hazard ratio: 0.76 vs. 0.69 per 10 mmol/L × years) (FIGURE 4). Since CETP 389 inhibition and the other pathways produced comparable effects per unit of cumulative 390 LDL-C reduction, these results suggest that CETP inhibition reduces ASCVD risk primarily 391 by lowering LDL-C.

392 Nine out of eleven lipid-lowering trials with cumulative LDL-C reductions 393 below 2.5 mmol/L × years did not achieve a statistically significant reduction in ASCVD 394 events, as indicated by 95% confidence intervals overlapping the null in FIGURE 4. Only two trials (PROVE-IT and IMPROVE-IT) with reductions below this threshold had 395 396 confidence intervals that did not overlap the null. These data suggest that the LDL-C 397 reductions in the evacetrapib and dalcetrapib trials were too small to yield a statistically 398 significant decrease in ASCVD events. Moreover, this issue appears not to be unique to 399 CETP inhibitors but applies to LDL-C lowering therapies in general. To demonstrate 400 stronger effects on clinical endpoints, future trials could target greater cumulative LDL-C 401 reductions.

403 Discussion

The failure of the early CETP inhibitors in cardiovascular outcomes trials surprised many and raised doubts about the efficacy of CETP inhibition in ASCVD prevention. In contrast, our study shows that individuals carrying a single defective *CETP* allele since birth, leading to lifelong partial CETP inhibition, have a significantly reduced risk of developing ASCVD. This finding aligns with previous genetic studies on both common and rare loss-of-function *CETP* variants across diverse populations,^{32,53-57} reinforcing the potential of CETP inhibition as a promising strategy for ASCVD prevention.

To reconcile the discrepancy between the promising genetic data and mixed clinical trial results, we applied the hypothesis that cumulative lifetime LDL-C exposure plays a critical role in ASCVD development. This concept aligns with the pathophysiology of atherosclerosis, which suggests that both the magnitude and duration of LDL-C exposure drive disease progression through plaque formation.¹⁷ A key strength of our study was the estimation of cumulative LDL-C differences over time, providing a more biologically accurate assessment of LDL-lowering effects on ASCVD risk.

418 By analyzing data from individuals with CETP and LDLR PTVs, along with 419 cardiovascular outcomes trials of lipid-lowering therapies, we identified a strong linear 420 relationship between reductions in cumulative LDL-C exposure and decreases in ASCVD 421 risk. Notably, clinical trials that did not achieve substantial and sustained LDL-C 422 reductions over time. regardless of the therapeutic mechanism, including CETP 423 inhibitors, statins, or PCSK9 inhibitors, were significantly less likely to show clinical 424 benefit. These findings suggest that the lack of efficacy seen in the evacetrapib and 425 dalcetrapib trials was not specific to the particular class of drugs but was instead due to 426 insufficient LDL lowering and the short duration of the trials.

427 Our analysis demonstrated that both LDL-C reduction magnitude and 428 treatment duration were independent predictors of ASCVD risk reduction. Furthermore, 429 we identified a significant interaction between these factors, providing strong support for 430 the cumulative LDL hypothesis. A key strength of the meta-analysis was the use of strict 431 exclusion criteria to eliminate trials that were likely to report inflated effect estimates.⁴³ 432 Our findings are consistent with another meta-analysis of 21 trials that focused on

433 minimizing bias from small-study effects while also excluding trials with less than 3 years
434 of follow-up.⁵⁸

435 These results indicate that instrumental variable analysis using human 436 genetics can yield accurate treatment effect estimates when time-varying exposures are 437 assessed and accounted for. Previous studies have suggested that genetic analyses may overestimate the impact of LDL-C lowering on ASCVD risk,⁵⁰ potentially due to imprecise 438 439 measurement of the exposure variable. Specifically, equating exposure to the effect of 440 genetic variants on LDL-C at a single time point assumes that ASCVD risk reduction is 441 driven by a constant, time-independent, and absolute LDL-C lowering. Given the 442 progressive nature of atherosclerosis and the variation in LDL-C levels throughout life, 443 this assumption may not be valid.

This highlights that an important difference between genetic and pharmacological effects lies in the timing and duration of exposure and the length of follow-up. Genetic exposures begin at conception and persist throughout life, whereas clinical trials administer treatments to adults and generally follow participants for only a few years. Since atherosclerosis can begin early in life and is driven by cumulative LDL-C retention,^{16,17} accounting for lifelong time-varying exposure is essential for accurate estimation of treatment effects.

451 In this study, we addressed this by modeling LDL-C reductions using population-averaged life-course trajectories. While this method improves accuracy over 452 453 assuming time-independent absolute LDL-C reductions, it has limitations. Specifically, 454 we did not account for individual variations in LDL-C trajectories across different 455 populations (besides correcting for baseline levels), nor did we consider complex, non-456 linear interactions with treatments or risk factors such as diabetes, hypertension, 457 inflammation, severely elevated Lipoprotein(a) levels, or lifestyle. Future studies should 458 aim to use within-sample LDL-C trajectories and consider individual-level models to 459 enhance the precision of cumulative LDL-C exposure measurements.

Another limitation of this study was that we did not investigate genetic CETP inhibition in its homozygous state. Heterozygous *CETP* PTV carriers showed LDL-C reductions of –0.19 mmol/L, whereas potent CETP inhibitors reduced LDL-C by up to five times more (–0.98 mmol/L).¹⁵ From these genetic data, it is unclear whether increased genetic CETP inhibition leads to proportionally greater benefits. However, anacetrapib

100 mg daily achieved 80% CETP inhibition and demonstrated similar clinical benefits to *CETP* PTV carriers (per unit of cumulative LDL-C lowering),^{13,59} suggesting that the genetic
effects may be generalizable (FIGURE 3).

These findings have important clinical implications that require confirmation in clinical trials. They suggest that maximizing the benefits of LDL-C lowering depends on achieving substantial and sustained reductions over extended periods. They also highlight the need for further research in early intervention and long-term adherence to both lifestyle and pharmacological lipid-lowering interventions. Future clinical trials should consider the impact of LDL-C over time in their design to better assess the efficacy of lipid-lowering therapies for ASCVD prevention.

In conclusion, we predict that future CETP inhibitor trials achieving
substantial and sustained LDL-C lowering will demonstrate efficacy in preventing ASCVD.
Our findings emphasize the importance of sustained LDL-C reduction over time and
support the continued investigation of CETP inhibition as a therapeutic strategy for
ASCVD prevention.

481 Acknowledgements

This research has been conducted using the UK Biobank Resource under Application
Number 148828. We thank the UK Biobank participants for their important contributions
to medical research. The graphical abstract was created in BioRender (Landfors, F. (2024)
https://BioRender.com/j51i966).

486 Funding

- 487 This work was supported by grants from the Northern Sweden Heart Fund, and received
- 488 financial support from New Amsterdam Pharma Company N.V.

489 Conflict of interest

Fredrik Landfors is a part-time clinical scientist at Lipigon Pharmaceuticals AB. John J.P.
Kastelein is the chief scientific officer of NewAmsterdam Pharma N.V. Elin Chorell has no
conflicts of interest to declare.

493 Data availability

494 UK Biobank data is available to authorized researchers. Researchers interested in 495 accessing the data must complete an application process with UK Biobank. The 496 identifiers for the UK Biobank datasets used in the analyses are described in the METHODS 497 section. All publicly available scientific data that were used for the analyses of this paper 498 are provided in the manuscript or supplemental material. Plots were digitized using the 499 University of Tennessee-Knoxville WebPlotDigitizer v.3.4 500 (https://web.eecs.utk.edu/~dcostine/personal/PowerDeviceLib/DigiTest/index.html).

502 Legends

503 Table 1

504 **Characteristics of the European-ancestry United Kingdom Biobank cohort.**

All measurements, except for the atherosclerotic cardiovascular disease-related primary
and secondary endpoints, were taken at the time of entry into the United Kingdom
Biobank. To protect privacy, cell counts of five or fewer are reported as '≤5'.

508 Figure 1

509 **Comparison of LDL cholesterol trajectories in genetic studies and clinical trials.**

510 This schematic compares LDL cholesterol trajectories from genetic effects versus clinical 511 interventions. The left panel shows a modest, lifelong reduction in LDL cholesterol 512 beginning at conception due to CETP protein-truncating variants (PTVs). In contrast, the 513 right panel illustrates a more substantial reduction starting in adulthood, as seen in the 514 Scandinavian Simvastatin Survival Study (4S). Despite differences in onset and magnitude, both approaches lead to similar reductions of cumulative LDL cholesterol 515 516 exposure over time. The cumulative LDL cholesterol lowering for each scenario 517 corresponds to the values shown on the x-axis of FIGURE 4.

518 Figure 2

519 Association of CETP protein-truncating variants with cardiovascular endpoints.

(A) Kaplan-Meier survival curves comparing cumulative survival (left panel) and eventfree survival (right panel) between carriers of *CETP* protein-truncating variants (PTVs) (n =
385) and non-carriers (n = 409,253) in the European-ancestry subset of the UK Biobank.
Shaded areas around each curve represent the 95% confidence intervals. Curves were
truncated when the at-risk population fell below 10 participants.

- 525 (B) Forest plot showing the association between *CETP* PTVs and primary and secondary526 cardiovascular endpoints.
- 527 (C) Forest plot showing the trans-ancestry meta-analysis combining UK Biobank results
 528 with data from previous studies of *CETP* PTVs.³² Ancestries are denoted as: 'Eur' for
 529 European, 'Afr.' for African, and 'S. As' for South Asian. 'ASCVD' denotes atherosclerotic
 530 cardiovascular disease, and "CHD" denotes coronary heart disease.

531 Figure 3

532 Atherosclerotic risk reduction from the magnitude and duration of LDL cholesterol 533 lowering in clinical trials.

534 Meta-regression scatterplot illustrating the association between atherosclerotic 535 cardiovascular disease (ASCVD) risk reduction and the interaction between LDL-C 536 lowering and median time of follow-up in clinical trials. The clinical trials investigated 537 statins, ezetimibe, PCSK9 and CETP inhibitors. Each point represents a clinical trial, with 538 size of the circles reflecting the weight of the trial in the meta-regression analysis. The 539 solid line shows the association between the observed treatment effects on 540 atherosclerotic vascular disease risk and the cumulative LDL differences (LDL × time) observed during follow-up, and the dashed lines represents the 95% confidence interval 541 (CI). 542

543 'QE' denotes test for residual heterogeneity

544 Figure 4

545 Relationship between cumulative LDL cholesterol reduction and atherosclerotic 546 cardiovascular disease risk reduction across multiple mechanisms.

547 The regression scatterplot shows the relationship between cumulative LDL cholesterol 548 (LDL-C) reduction (measured in LDL-C plaque years) and atherosclerotic cardiovascular 549 disease (ASCVD) risk reduction achieved through CETP inhibition, statins, ezetimibe, PCSK9 inhibitors, and the LDL receptor (LDLR). Each point represents a clinical trial or 550 551 genetics study, with circle sizes reflecting study weight in the meta-analysis. Risk 552 reductions were observed either between treatment arms or between carriers of protein-553 truncating variants (PTVs) and controls. Solid lines indicate meta-analysis treatment effect estimates, with shaded areas showing 95% confidence intervals (CIs). Individual 554 555 study effect estimates are marked by data points with attached vertical lines representing 556 95% Cls.

557 'HR' denotes hazard ratio, and 'IRR' denotes incidence rate ratio. Drug targets are 558 indicated as: 'HMGCR' for HMG-CoA Reductase (statins), 'NPC1L1' for Niemann-Pick C1-559 Like 1 (ezetimibe), and 'PCSK9' for PCSK9 inhibitors. 'LDLR PTVs' refer to protein-560 truncating variants in the LDL receptor.

- 561 † To simplify visualization, carriers of LDLR PTVs (familial hypercholesterolemia-
- 562 associated variants) were used as the reference group. Compared to controls (n =
- 563 409,539), *LDLR* PTV carriers (n = 99) had a higher ASCVD risk, with a hazard ratio of 4.44
- 564 (95% CI: 3.27–6.04).
- 565 Appendices
- 566 Supplemental note
- 567 **R script for estimating LDL-C Plaque Years Difference.**
- 568 This script provides reproducible code for estimating cumulative LDL cholesterol (LDL-C)
- lowering from clinical trials or genetic exposures, as described in the paper.
- 570 Supplemental figures
- 571 Supplemental figure 1

572 **Association between HDL cholesterol and** *CETP* Loss-Of-Function Transcript Effect 573 **Estimator (LOFTEE) protein-truncating variant (PTV) classifications.**

Tukey Box plot showing there were no meaningful differences between LOFTEE PTV 574 575 classifications with regards to plasma HDL cholesterol (HDL-C) levels. The analysis was 576 conducted in 357,794 European ancestry United Kingdom Biobank participants. The association between CETP PTV classifications were tested using analysis of variance. 577 Welch's F test indicated unequal variances ($P = 3.0 \times 10^{-25}$). Post hoc tests indicated there 578 579 were no significant differences between predicted low-confidence and high-confidence 580 CETP PTVs (P = 0.55). However, HDL-C levels were elevated in both high- and lowconfidence CETP PTV carriers compared to non-carriers ($P = 2.3 \times 10^{-12}$, and $P = 2.4 \times 10^{-6}$, 581 582 respectively). There were only two individuals carrying non-classified predicted CETP 583 PTVs, and their HDL-C levels were nominally higher than non-carriers, but nominally 584 lower than low- or high-confidence *CETP* PTV carriers ($\hat{\mu}_{mean}$ = 1.55 mmol/L). Since the 585 HDL-C levels were similar across the LOFTEE categories, we conclude that LOFTEE 586 classifications were irrelevant as they did not predict the CETP PTVs impact on CETP 587 activity as measured through plasma HDL-C concentrations.

588 Supplemental figure 2

589 Sensitivity analysis of atherosclerotic risk reduction from cumulative LDL 590 cholesterol lowering, including trials terminated early due to efficacy.

- 591 The meta-analysis followed the same procedure as in **FIGURE 3** but retained trials that
- 592 were stopped early for efficacy.
- 593 Supplemental figure 3
- 594 Leave-one-out sensitivity analysis of the pooled effect size and heterogeneity for
- 595 ASCVD risk reduction from cumulative LDL-C lowering, based on SUPPLEMENTAL
- 596 **FIGURE 2.**
- 597 Each study was sequentially excluded to measure its influence on the overall association.
- 598 Supplemental figure 4

599 Sensitivity analysis of atherosclerotic risk reduction from cumulative LDL 600 cholesterol lowering, including and penalizing trials terminated early due to efficacy. 601 The meta-analysis followed the same procedure as in FIGURE 4 but included trials 602 stopped early for efficacy, penalizing their effect estimates (natural logarithm of the 603 hazard ratio) by multiplication with their information criterion (see the METHODS section 604 for definition).

605 Supplemental figure 5

606 Leave-one-out sensitivity analysis of the pooled effect size and heterogeneity for

- 607 atherosclerotic cardiovascular disease risk reduction from cumulative LDL
- 608 cholesterol lowering, based on SUPPLEMENTAL FIGURE 4.
- Each study was sequentially excluded to assess its influence on the overall association.
- 610 Supplemental figure 6
- 611 **Sensitivity analysis of atherosclerotic risk reduction from cumulative LDL** 612 **cholesterol lowering, excluding non-double-blind clinical trials.**
- 613 The meta-analysis was conducted using the same methods as in **FIGURE 4** but excluded
- 614 non-double-blind trials.
- 615 Supplemental figure 7
- 616 Leave-one-out sensitivity analysis of the pooled effect size and heterogeneity for
- 617 atherosclerotic cardiovascular disease risk reduction from cumulative LDL
- 618 cholesterol lowering, based on SUPPLEMENTAL FIGURE 6.
- Each study was sequentially excluded to assess its influence on the overall association
- 620 between LDL cholesterol reduction and ASCVD risk.

621 Supplemental figure 8

- 622 Leave-one-out sensitivity analysis of the pooled effect size and heterogeneity for
- 623 atherosclerotic cardiovascular disease risk reduction from cumulative LDL
- 624 cholesterol lowering, based on FIGURE 4.
- Each study was sequentially excluded to assess its influence on the overall association
- 626 between LDL cholesterol reduction and ASCVD risk.

627 Supplemental figure 9

- Supplemental Figure 9. Meta-regression analyses for atherosclerotic disease risk
 reduction based on LDL-C reduction times the median time of follow-up.
- 630 (A) The left scatterplot regression line shows the association between LDL-C (low-density
- 631 lipoprotein cholesterol) reduction and atherosclerotic cardiovascular disease (ASCVD)
- 632 risk reduction conditioning on median time of follow-up. The right scatterplot regression
- 633 line shows ASCVD risk as a function of adjusted median time of follow-up by LDL-C634 reduction.
- (B) The scatterplots show meta-regressions with an interaction term between LDL-C
 reduction and median time of follow-up. The top plot regression slope shows the adjusted
 ASCVD risk as a function of the interaction between LDL-C reduction and median time of
 follow-up (mmol/L × years). The two bottom plots show the separate effects of LDL-C
 reduction (left) and median time of follow-up (right) on ASCVD risk, taking the interaction
 term into account.
- 641 Dashed lines indicate confidence intervals. Larger circle sizes correspond to studies with
- 642 greater weight in the analysis. 'HR' denotes hazard ratio, and 'IRR' denotes incidence rate 643 ratio.

644 Supplemental figure 10

645 **Supplemental Figure 10. Meta-regression sensitivity and multi-model inference** 646 **analyses**

(A) The table shows adjusted models of the interaction between LDL cholesterol (LDL-C)
reduction and the median time of follow-ups across atherosclerotic cardiovascular
disease (ASCVD) risk reduction in clinical trials. Model 1 includes the interaction between
LDL-C reduction and median time of follow-up, while models 2–6 adds a single
adjustment for either baseline LDL-C, annualized risk, cumulative risk, mean age, and

- 652 year of publication. The interaction regression coefficients (β), standard errors (SE), p-
- values, and permutation-based p-values are shown in separate columns.
- 654 (B) This bar plot shows the ranking of the importance of predictor variables in explaining
- 655 ASCVD risk reduction as observed in the clinical trials.
- 656 Supplemental tables
- 657 Supplemental table 1
- 658 UK Biobank CETP protein-truncating variants.
- 659 This table lists the protein-truncating variants (PTVs) in CETP (encoding the cholesteryl
- 660 ester transfer protein) that were analyzed in the United Kingdom Biobank (see **STEP 1**). It
- 661 includes variant identifiers, genomic positions, allele frequencies, and Ensembl Variant
- 662 Effect Predictor predicted consequences.

663 Supplemental table 2

664 **Cumulative LDL cholesterol exposure versus atherosclerotic cardiovascular disease** 665 **risk.**

This table includes summary data from clinical trials and genetic association studies relevant to the analysis of cumulative LDL cholesterol exposure in relation to atherosclerotic cardiovascular disease risk, which are presented in **FIGURE 3** and

669 **SUPPLEMENTAL FIGURES 2-12.**

670 Supplemental table 3

671 UK Biobank LDLR protein-truncating variants.

This table lists the protein-truncating variants (PTVs) in *LDLR* (encoding the low-density
lipoprotein receptor) that were analyzed in the United Kingdom Biobank (see STEP 1). It
includes variant identifiers, genomic positions, allele frequencies, and Ensembl Variant

- 675 Effect Predictor predicted consequences.
- 676

677 Supplemental table 4

678 Low-density lipoprotein cholesterol life-course trajectories.

679 This table presents averaged life-course trajectories of low-density lipoprotein (LDL)

680 cholesterol levels derived from population-based cohorts.^{17,46,47} These data were used in

the analyses presented in FIGURE 1, FIGURE 4, and SUPPLEMENTAL FIGURES 2–8.

medRxiv preprint doi: https://doi.org/10.1101/2024.12.02.24318306; this version posted December 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

References 683

684 Morton RE, Zilversmit DB. Purification and characterization of lipid transfer 1. 685 protein(s) from human lipoprotein-deficient plasma. J Lipid Res. Sep 1982;23(7):1058-686 67.

687 2. Drayna D, Jarnagin AS, McLean J, et al. Cloning and sequencing of human 688 cholesteryl ester transfer protein cDNA. Nature. 1987 Jun 18-24 1987;327(6123):632-4. 689 doi:10.1038/327632a0

690 3. Tall AR, Rader DJ. Trials and Tribulations of CETP Inhibitors. Circ Res. Jan 05 691 2018;122(1):106-112. doi:10.1161/CIRCRESAHA.117.311978

692 Millar JS, Reyes-Soffer G, Jumes P, et al. Anacetrapib lowers LDL by 4. 693 increasing ApoB clearance in mildly hypercholesterolemic subjects. J Clin Invest. Jun 694 2015;125(6):2510-22. doi:10.1172/JCI80025

695 Ikewaki K, Nishiwaki M, Sakamoto T, et al. Increased catabolic rate of low 5. 696 density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J Clin 697 Invest. Sep 1995;96(3):1573-81. doi:10.1172/JCI118196

698 Nicholls SJ, Ruotolo G, Brewer HB, et al. Cholesterol Efflux Capacity and 6. 699 Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. JAm Coll Cardiol. Nov 17 2015;66(20):2201-2210. 700

701 doi:10.1016/j.jacc.2015.09.013

- 702 7. Yvan-Charvet L, Kling J, Pagler T, et al. Cholesterol efflux potential and 703 antiinflammatory properties of high-density lipoprotein after treatment with niacin or 704 anacetrapib. Arterioscler Thromb Vasc Biol. Jul 2010;30(7):1430-8.
- 705 doi:10.1161/ATVBAHA.110.207142

706 Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at 8. 707 high risk for coronary events. N Engl J Med. Nov 22 2007;357(21):2109-22.

708 doi:10.1056/NEJMoa0706628

709 Johns DG, Duffy J, Fisher T, Hubbard BK, Forrest MJ. On- and off-target 9. 710 pharmacology of torcetrapib: current understanding and implications for the structure 711 activity relationships (SAR), discovery and development of cholesteryl ester-transfer 712 protein (CETP) inhibitors. Drugs. Mar 05 2012;72(4):491-507. doi:10.2165/11599310-713 00000000-00000

714 10. Kastelein JJP, Hsieh A, Dicklin MR, Ditmarsch M, Davidson MH. Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments. Curr Atheroscler Rep. Feb 715

716 2024;26(2):35-44. doi:10.1007/s11883-023-01184-1

717 Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with 11. 718 a recent acute coronary syndrome. N Engl J Med. Nov 29 2012;367(22):2089-99. 719 doi:10.1056/NEJMoa1206797

720 Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and Cardiovascular 12. 721 Outcomes in High-Risk Vascular Disease. N Engl J Med. May 18 2017;376(20):1933-

722 1942. doi:10.1056/NEJMoa1609581

723 13. Bowman L, Hopewell JC, Chen F, et al. Effects of Anacetrapib in Patients 724 with Atherosclerotic Vascular Disease. N Engl J Med. Sep 28 2017;377(13):1217-1227. 725 doi:10.1056/NEJMoa1706444

726 14. Johns DG, Wang SP, Rosa R, et al. Impact of drug distribution into adipose 727 on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as 728 a test case. Pharmacol Res Perspect. Dec 2019;7(6):e00543. doi:10.1002/prp2.543

729 15. Nicholls SJ, Ditmarsch M, Kastelein JJ, et al. Lipid lowering effects of the 730 CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized 731 phase 2 trial. Nat Med. Aug 2022;28(8):1672-1678. doi:10.1038/s41591-022-01936-7 732 16. HOLMAN RL, McGILL HC, STRONG JP, GEER JC. The natural history of 733 atherosclerosis: the early aortic lesions as seen in New Orleans in the middle of the of the 20th century. Am J Pathol. 1958;34(2):209-35. 734 735 Ference BA, Braunwald E, Catapano AL. The LDL cumulative exposure 17. 736 hypothesis: evidence and practical applications. Nat Rev Cardiol. Oct 2024;21(10):701-737 716. doi:10.1038/s41569-024-01039-5 738 Rivas MA, Pirinen M, Conrad DF, et al. Human genomics. Effect of predicted 18. 739 protein-truncating genetic variants on the human transcriptome. Science. May 08 740 2015;348(6235):666-9. doi:10.1126/science.1261877 741 DeBoever C, Tanigawa Y, Lindholm ME, et al. Medical relevance of protein-19. 742 truncating variants across 337,205 individuals in the UK Biobank study. Nat Commun. 743 Apr 24 2018;9(1):1612. doi:10.1038/s41467-018-03910-9 744 20. Dhindsa RS, Burren OS, Sun BB, et al. Rare variant associations with 745 plasma protein levels in the UK Biobank. Nature. Oct 2023;622(7982):339-347. 746 doi:10.1038/s41586-023-06547-x 747 Minikel EV, Karczewski KJ, Martin HC, et al. Evaluating drug targets through 21. 748 human loss-of-function genetic variation. Nature. May 2020;581(7809):459-464. 749 doi:10.1038/s41586-020-2267-z 750 22. Trajanoska K, Bhérer C, Taliun D, Zhou S, Richards JB, Mooser V. From target 751 discovery to clinical drug development with human genetics. Nature. Aug 752 2023;620(7975):737-745. doi:10.1038/s41586-023-06388-8 753 Minikel EV, Painter JL, Dong CC, Nelson MR. Refining the impact of genetic 23. 754 evidence on clinical success. Nature. May 2024;629(8012):624-629. 755 doi:10.1038/s41586-024-07316-0 Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource 756 24. 757 for identifying the causes of a wide range of complex diseases of middle and old age. 758 PLoS Med. Mar 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779 759 Szustakowski JD, Balasubramanian S, Kvikstad E, et al. Advancing human 25. 760 genetics research and drug discovery through exome sequencing of the UK Biobank. Nat 761 Genet. Jul 2021;53(7):942-948. doi:10.1038/s41588-021-00885-0 762 26. McLaren W, Gil L, Hunt SE, et al. The Ensembl Variant Effect Predictor. 763 Genome Biol. Jun 06 2016;17(1):122. doi:10.1186/s13059-016-0974-4 Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint 764 27. 765 spectrum quantified from variation in 141,456 humans. Nature. May 766 2020;581(7809):434-443. doi:10.1038/s41586-020-2308-7 767 Yamamoto K, Sonehara K, Namba S, et al. Genetic footprints of assortative 28. 768 mating in the Japanese population. Nat Hum Behav. Jan 2023;7(1):65-73. 769 doi:10.1038/s41562-022-01438-z 770 29. Abdellaoui A, Hugh-Jones D, Yengo L, et al. Genetic correlates of social 771 stratification in Great Britain. Nat Hum Behav. Dec 2019;3(12):1332-1342. 772 doi:10.1038/s41562-019-0757-5 773 30. Howe LJ, Nivard MG, Morris TT, et al. Within-sibship genome-wide 774 association analyses decrease bias in estimates of direct genetic effects. Nat Genet. 775 May 2022;54(5):581-592. doi:10.1038/s41588-022-01062-7

776 31. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust 777 relationship inference in genome-wide association studies. Bioinformatics. Nov 15 778 2010;26(22):2867-73. doi:10.1093/bioinformatics/btq559 779 32. Nomura A, Won HH, Khera AV, et al. Protein-Truncating Variants at the 780 Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease. Circ Res. 781 Jun 23 2017;121(1):81-88. doi:10.1161/CIRCRESAHA.117.311145 782 FIRTH D. BIAS REDUCTION OF MAXIMUM-LIKELIHOOD-ESTIMATES. Article. 33. 783 Biometrika. MAR 1993 1993;80(1):27-38. doi:10.1093/biomet/80.1.27 784 Burger PM, Dorresteijn JAN, Koudstaal S, et al. Course of the effects of LDL-34. 785 cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60 786 randomized controlled trials. Atherosclerosis. Sep 2024;396:118540. 787 doi:10.1016/j.atherosclerosis.2024.118540 788 Khan SU, Khan MU, Valavoor S, et al. Association of lowering apolipoprotein 35. 789 B with cardiovascular outcomes across various lipid-lowering therapies: Systematic 790 review and meta-analysis of trials. Eur J Prev Cardiol. Aug 2020;27(12):1255-1268. 791 doi:10.1177/2047487319871733 792 Navarese EP, Robinson JG, Kowalewski M, et al. Association Between 36. 793 Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A 794 Systematic Review and Meta-analysis. JAMA. Apr 17 2018;319(15):1566-1579. 795 doi:10.1001/jama.2018.2525 796 37. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 797 diabetes mellitus undergoing hemodialysis. N Engl J Med. Jul 21 2005;353(3):238-48. 798 doi:10.1056/NEJMoa043545 799 Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and 38. 800 cardiovascular events in patients undergoing hemodialysis. N Engl J Med. Apr 02 801 2009;360(14):1395-407. doi:10.1056/NEJMoa0810177 802 39. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with 803 systolic heart failure. N Engl J Med. Nov 29 2007;357(22):2248-61. 804 doi:10.1056/NEJMoa0706201 805 40. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on 806 early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a 807 randomized controlled trial. JAMA. Apr 04 2001;285(13):1711-8. 808 doi:10.1001/jama.285.13.1711 809 41. Taguchi I, limuro S, Iwata H, et al. High-Dose Versus Low-Dose Pitavastatin 810 in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized 811 Superiority Trial. Circulation. May 08 2018;137(19):1997-2009. 812 doi:10.1161/CIRCULATIONAHA.117.032615 813 Grinspoon SK, Fitch KV, Zanni MV, et al. Pitavastatin to Prevent 42. 814 Cardiovascular Disease in HIV Infection. N Engl J Med. Aug 24 2023;389(8):687-699. 815 doi:10.1056/NEJMoa2304146 816 Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for 43. 817 benefit and estimation of treatment effects: systematic review and meta-regression 818 analysis. JAMA. Mar 24 2010;303(12):1180-7. doi:10.1001/jama.2010.310 819 44. Hernán MA. The hazards of hazard ratios. Epidemiology. Jan 2010;21(1):13-820 5. doi:10.1097/EDE.0b013e3181c1ea43

821 45. McGowan MP, Hosseini Dehkordi SH, Moriarty PM, Duell PB. Diagnosis and 822 Treatment of Heterozygous Familial Hypercholesterolemia. J Am Heart Assoc. Dec 17 823 2019;8(24):e013225. doi:10.1161/JAHA.119.013225 824 Gozlan O, Gross D, Gruener N. Lipoprotein levels in newborns and 46. 825 adolescents. Clin Biochem. Aug 1994;27(4):305-6. doi:10.1016/0009-9120(94)90033-7 826 47. Skinner AC, Steiner MJ, Chung AE, Perrin EM. Cholesterol curves to identify 827 population norms by age and sex in healthy weight children. Clin Pediatr (Phila). Mar 828 2012;51(3):233-7. doi:10.1177/0009922811430344 829 Labrecque JA, Swanson SA. Interpretation and Potential Biases of 48. 830 Mendelian Randomization Estimates With Time-Varying Exposures. Am J Epidemiol. Jan 831 01 2019;188(1):231-238. doi:10.1093/aje/kwy204 832 49. Morris TT, Heron J, Sanderson ECM, Davey Smith G, Didelez V, Tilling K. 833 Interpretation of Mendelian randomization using a single measure of an exposure that 834 varies over time. Int J Epidemiol. Dec 13 2022;51(6):1899-1909. doi:10.1093/ije/dyac136 835 Burgess S, Butterworth A, Malarstig A, Thompson SG. Use of Mendelian 50. 836 randomisation to assess potential benefit of clinical intervention. BMJ. Nov 06 837 2012;345:e7325. doi:10.1136/bmj.e7325 838 Higgins JP, Thompson SG. Controlling the risk of spurious findings from 51. 839 meta-regression. Stat Med. Jun 15 2004;23(11):1663-82. doi:10.1002/sim.1752 840 Hovingh GK, Kastelein JJ, van Deventer SJ, et al. Cholesterol ester transfer 52. 841 protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, 842 double-blind, placebo-controlled phase 2 trial. Lancet. Aug 01 2015;386(9992):452-60. 843 doi:10.1016/S0140-6736(15)60158-1 844 53. Johannsen TH, Frikke-Schmidt R, Schou J, Nordestgaard BG, Tybjærg-845 Hansen A. Genetic inhibition of CETP, ischemic vascular disease and mortality, and 846 possible adverse effects. JAm Coll Cardiol. Nov 13 2012;60(20):2041-8. 847 doi:10.1016/j.jacc.2012.07.045 848 Ference BA, Kastelein JJP, Ginsberg HN, et al. Association of Genetic 54. 849 Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and 850 Cardiovascular Risk. JAMA. Sep 12 2017;318(10):947-956. 851 doi:10.1001/jama.2017.11467 852 55. Nordestgaard LT, Christoffersen M, Lauridsen BK, et al. Long-term Benefits and Harms Associated With Genetic Cholesteryl Ester Transfer Protein Deficiency in the 853 854 General Population. JAMA Cardiol. Jan 01 2022;7(1):55-64. 855 doi:10.1001/jamacardio.2021.3728 856 Cupido AJ, Reeskamp LF, Hingorani AD, et al. Joint Genetic Inhibition of 56. 857 PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial 858 Mendelian Randomization Study. JAMA Cardiol. Sep 01 2022;7(9):955-964. 859 doi:10.1001/jamacardio.2022.2333 860 57. Dunca D, Chopade S, Gordillo-Marañón M, et al. Comparing the effects of 861 CETP in East Asian and European ancestries: a Mendelian randomization study. Article. 862 Nature Communications. JUN 21 2024 2024;15(1)ARTN 5302. doi:10.1038/s41467-024-863 49109-z 864 58. Wang N, Woodward M, Huffman MD, Rodgers A. Compounding Benefits of 865 Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: 866 Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes. Jun 867 2022;15(6):e008552. doi:10.1161/CIRCOUTCOMES.121.008552

- 868 59. Krishna R, Bergman AJ, Jin B, et al. Multiple-dose pharmacodynamics and
- 869 pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP)
- 870 inhibitor, in healthy subjects. Clin Pharmacol Ther. Dec 2008;84(6):679-83.
- doi:10.1038/clpt.2008.109 871

(GRAPHICAL ABSTRACT)



(TABLE 1)

Step 1

Table 1. Cohort characteristics	Mean (95% Cl) / No. (%)			
	Complete observations (% missing)	Controls (n = 409 253)	Heterozygous <i>CETP</i> PTV carriers (n = 385)	P value
Age (years)	409 638 (0.0%)	56.8 (56.8-56.8)	56.7 (55.9-57.4)	0.71
Male	409 638 (0.0%)	188 542 (46.1%)	178 (46.2%)	0.96
Blood pressure (mmHg)				
Systolic	382 697 (6.6%)	139.9 (139.9-140.0)	140.8 (138.7-142.9)	0.41
Diastolic	382 708 (6.6%)	82.2 (82.2-82.2)	83.5 (82.2-84.7)	0.043
Weight (kg)	408 454 (0.3%)	78.2 (78.2-78.3)	78.1 (76.5-79.7)	0.92
BMI (kg/m²)	408 306 (0.4%)) 27.4 (27.4-27.4)	27.4 (27.0-27.9)	0.88
Self-reported diabetes status at recruitment	408 727 (0.3%)	19 783 (4.8%)	21 (5.5%)	0.55
Self-reported smoking status at recruitment	408 234 (0.4%)	42 677 (10.4%)	37 (9.6%)	0.68
recruitment	408 511 (0.3%)	66 879 (16.3%)	48 (12.5%)	0.039
Lipids (mmol/L)				
HDL cholesterol	357 796 (12.7%)	1.45 (1.45-1.45)	1.87 (1.81-1.92)	9 × 10 ⁻³⁷
LDL cholesterol, direct	390 187 (4.8%)	3.57 (3.57-3.57)	3.39 (3.30-3.47)	3 × 10 ⁻⁵
LDL cholesterol, Friedewald	357 486 (12.8%)) 3.46 (3.46-3.47)	3.23 (3.13-3.34)	2 × 10 ⁻⁵
Non-HDL cholesterol	357 731 (12.7%)	4.26 (4.26-4.26)	4.05 (3.94-4.16)	2 × 10 ⁻⁴
Remnant cholesterol	357 145 (12.9%)	0.69 (0.69-0.69)	0.65 (0.62-0.68)	0.017
Triglycerides	390 628 (4.7%)) 1.75 (1.75-1.76)	1.78 (1.67-1.90)	0.06
Lipoproteins				
Apolipoprotein B (g/L)	389 028 (5.1%)) 1.04 (1.03-1.04)	0.97 (0.95-1.00)	6 × 10 ⁻⁷
Apolipoprotein A-I (g/L)	355 784 (13.2%)	1.54 (1.54-1.54)	1.73 (1.70-1.77)	6 × 10 ⁻²³
Lipoprotein(a) (nmol/L)	311 427 (24.0%)	44.0 (43.8-44.2)	37.5 (32.9-43.0)	0.021
Endpoints during follow-up				
Primary				
Any atherosclerotic disease	409 638 (0.0%)	61052 (14.9%)	39 (10.1%)	0.008
Secondary				
Coronary heart disease	409 638 (0.0%)	52666 (12.9%)	35 (9.1%)	0.027
Ischemic stroke	409 638 (0.0%)) 10491 (2.6%)	6 (1.6%)	0.26
Myocardial infarction	409 631 (0.1%)	20600 (5.0%)	17 (4.4%)	0.73
Cardiovascular death Major adverse	409 638 (0.0%)	4167 (1.0%)	≤5 (≤1.3%)	
cardiovascular events	409 633 (0.1%)) 29484 (7.2%)	21 (5.5%)	0.20
Peripheral atherosclerosis	409 638 (0.0%)) 3667 (0.9%)	≤5 (≤1.3%)	
All-cause death Any atherosclerotic disease or all-cause	409 638 (0.0%)	36641 (9.0%)	27 (7.0%)	0.21
death	409 638 (0.0%)	83510 (20.4%)	59 (15.3%)	0.013

(FIGURE 1)

A. Cumulative LDL Cholesterol Exposure Difference when the Trajectory is Altered by Genetics

B. Cumulative LDL Cholesterol Exposure Difference when the Trajectory is Altered in a Drug Trial



(FIGURE 2)

A. Survival Analysis of Atherosclerotic Events in the UK Biobank

Cumulative Events:



No. at Risk (%)

Ctrl	408538 (100)	403397 (99)	341176 (83)	206277 (50)	39582 (10)
PTV	385 (100)	383 (99)	332 (86)	201 (52)	34 (9)

B. Association of CETP PTVs with UK Biobank Cardiovascular Endpoints

Endpoint	Hazard ratio (95% CI)	
Any atherosclerotic event (61 091 cases)	0.65 (0.48-0.90)	-8-
Coronary heart disease (52 701 cases)	0.69 (0.49–0.96)	-8-
lschemic stroke (10 497 cases)	0.61 (0.27–1.36)	
Myocardial infarction (20 617 cases)	0.87 (0.54–1.40)	
Cardiovascular death (4169 cases)	0.52 (0.13–2.06)	
Major adverse cardiovascular eve (29 505 cases)	0.75 (0.49–1.14)	
Peripheral atherosclerosis (3671 cases)	1.18 (0.44–3.15)	
(36 669 cases)	0.80 (0.55–1.16)	
cause death (83 570 cases)	0.72 (0.56–0.93)	- B -



Event-free Survival: 100 CETP PTV Carriers 90 Controls Event-Free Survival (%) 80 70 60 50 · Mean Event-free Survival (Age=80): 40 -Ctrl, 77.0 Years (95% Cl, 76.9-77.0). 30 · PTV, 78.1 Years (95% CI, 77.5-78.7). 20 10 0 408540 (100) 402891 (98) 340509 (83) 206241 (50) 39714 (10) 387 (100) 384 (99) 334 (86) 202 (52) 35 (9)

Ctrl	408538 (100)	403397 (99)	341176 (83)	206277 (50)	39582 (10)
PTV	385 (100)	383 (99)	332 (86)	201 (52)	34 (9)

C. Trans-Ancestry Meta-Analysis of CETP PTVs

Endpoint	Odds ratio (95% CI)	
UK Biobank, Any ASCVD Eur. (61 091 cases)	0.64 (0.46- 0.90)	
UK Biobank, Any ASCVD Afr. (715 cases)	1.57 (0.27– 9.01)	
UK Biobank, Any ASCVD S.As. (1528 cases)	3.08 (0.46-20.74)	
Nomura et al. 2017, CHD Trans-ancestry (32 234 cases)	0.70 (0.54– 0.90)	
Pooled estimate (95 568 cases)	0.70 (0.57– 0.85)	
Meta-analysis <i>P</i> value = 4.7×10^{-4}		

Heterogeneity: Q = 3.39, P value = 0.34, I² = 11.5%



(FIGURE 3)

$\ensuremath{\mathsf{ASCVD}}$ Risk Reduction vs. Interaction between LDL-C Lowering and Time of Follow-up



LDL-C Reduction × Time of Follow-up (mmol/L × years)

(FIGURE 4)

1.00 **CETP** Inhibition Hazard ratio, 0.76 per 10-mmol/L × years (95% CI, 0.64-0.89) Heterogeneity: Q = 2.4 (Het. P value = 0.49), $I^2 = 0\%$ Other (HMGCR, NPC1L1, PCSK9, LDLR) Hazard ratio, 0.69 per 10-mmol/L × years (95% CI, 0.66-0.71) CETP PTVs (Genetic) Heterogeneity: Q = 41.2 (Het. P value = 0.11), I² = 24.7% 0.20 LDLR PTVs (Genetic)[†] 0.10 10 30 Ò 20 40 50 CETP PCSK9 HMGCR (statins) NPC1L1 (ezetimibe) LDLR : ODYSSEY OUTCOMES (Alirocumab, PCSK9) AURORA (Rosuvastatin, HMGCR) IMPROVE-IT (Ezetimibe, NPC1L1) ALLHAT-LLT (Pravastatin, HMGCR) REVEAL (Anacetrapib, CETP) ASPEN (Atorvastatin, HMGCR) ACCELERATE (Evacetrapib, CETP) Risk of Atherosclerotic Disease (HR/IRR) SEARCH (Simvastatin, HMGCR) SHARP (Simvastatin/Ezetimibe, HMGCR/NPC1L1) -OUTCOMES (Dalcetrapib, CETP) 4D (Ato statin, HMGCR) CORONA (Rosuvastatin, HMGCR) · LIPID (Pravastatin, HMGCR) ALERT (Fluvastatin, HMGCR) SPARCL (Atorvastatin, HMGCR) SEAS (Simvastatin/Ezetimibe, HMGCR/NPC1L1) 1.00 4S (Simvastatin HMGCR) 0.90 0.80 0.70 RACING (Ezetimibe, NPC1L1) WOSCOPS (Pravastatin, HMGCR) 0.60 MIRACL (Atorvastatin, HMGCR) RE 1 & 2 (Bococizumab, PCSK9) HIJ-PROPER (Ezetimibe, NPC1L1) **CETP PTVs (Genetic)** FOURIER (Evolucumab, PCSK9) A to Z (Simvastatin, HMGCR) ALLIANCE (Atorvastatin, HMGCR) PROSPER (Pravastatin, HMGCR) HOPE 3 (Rosuvastatin, HMGCR) 0.50 IDEAL (Atorvastatin, HMGCR) PROVE-IT (Atorvastatin, HMGCR) TNT (Atorvastatin, HMGCR) CARE (Pravastatin, HMGCR) MEGA (Pravastatin HMGCB) · LIPS (Fluvastatin, HMGCR) HPS (Simvastatin, HMGCR) 2.5 7.5 0 5 10 LDL-C Plaque Years Difference (mmol/L × years)

Comparison of ASCVD Risk Reduction and Cumulative LDL-C Exposure: CETP Inhibition vs. Guideline-Recommended Lipid-Lowering Therapies and LDLR PTVs

(SUPPLEMENTAL FIGURE 1)



Protein-Truncating Variant Annotation (Loss-of-Function Transcript Effect Estimator [LOFTEE])

(SUPPLEMENTAL FIGURE 2)

Comparison of ASCVD Risk and Cumulative LDL-C Exposure: CETP Inhibition vs. Guideline-Recommended Lipid-Lowering Therapies and LDLR PTVs



(SUPPLEMENTAL FIGURE 3)

Effect size & Heterogeneity

Leave-one-out effect size sensitivity analysis of statins, ezetimibe, PCSK9 inhibition, and LDLR PTVs



Leave-one-out effect size sensitivity analysis of CETP inhibition



Sorted by Effect Size

(SUPPLEMENTAL FIGURE 4)

Comparison of ASCVD Risk and Cumulative LDL-C Exposure: CETP Inhibition vs. Guideline-Recommended Lipid-Lowering Therapies and LDLR PTVs



(SUPPLEMENTAL FIGURE 5)

Effect size & Heterogeneity

Leave-one-out effect size sensitivity analysis of statins, ezetimibe, PCSK9 inhibition, and LDLR PTVs

Omitting LDLR PTVs (Genetic)		$\hat{\theta}_{*} = -0.42 [-0.470.38]; l^{2} = 12\%$
Omitting 4S (Simvastatin, HMGCR)		$\hat{\theta}_{*} = -0.40 [-0.430.36]; l^{2} = 24\%$
Omitting CORONA (Rosuvastatin, HMGCR)		$\hat{\theta} = -0.39 [-0.42 - 0.35]; I^2 = 25\%$
Omitting SEARCH (Simvastatin, HMGCR)		$\hat{\theta} = -0.38 [-0.42 - 0.35]; I^2 = 28\%$
Omitting SEAS (Simvastatin/Ezetimibe, HMGCR/NPC1L1)		$\hat{\theta} = -0.38 [-0.42 - 0.35]; I^2 = 28\%$
Omitting IMPROVE-IT (Ezetimibe, NPC1L1)		$\hat{\theta} = -0.38 [-0.42 - 0.35]; I^2 = 29\%$
Omitting AURORA (Rosuvastatin, HMGCR)		$\hat{\theta}_{1} = -0.38 [-0.42 - 0.35]; I^{2} = 28\%$
Omitting 4D (Atorvastatin, HMGCR)		$\hat{\theta} = -0.38 [-0.42 - 0.35]; I^2 = 29\%$
Omitting ASPEN (Atorvastatin, HMGCR)		$\hat{\theta} = -0.38 [-0.42 - 0.35]; I^2 = 29\%$
Omitting ALLHAT-LLT (Pravastatin, HMGCR)		$\hat{\theta} = -0.38 [-0.42 - 0.35]; I^2 = 29\%$
Omitting ALERT (Fluvastatin, HMGCR)		$\hat{\theta}_{1} = -0.38 [-0.42 - 0.35]; l^{2} = 29\%$
Omitting GISSI-P (Pravastatin, HMGCR)		$\hat{\theta} = -0.38 [-0.42 - 0.35]; I^2 = 29\%$
Omitting RACING (Ezetimibe, NPC1L1)		$\hat{\theta} = -0.38 [-0.42 - 0.35]; I^2 = 29\%$
Omitting MIRACL (Atorvastatin, HMGCR)		$\hat{\theta} = -0.38 [-0.42 - 0.35]; l^2 = 28\%$
Omitting AF/TexCAPS (Lovastatin, HMGCR)		$\hat{\theta}_{+} = -0.38 [-0.42 - 0.35]; I^2 = 29\%$
Omitting HIJ-PROPER (Ezetimibe, NPC1L1)		$\hat{\theta}_{\tau} = -0.38 \left[-0.420.35 \right]; I^2 = 29\%$
Omitting TST (Statin/Ezetimibe, HMGCR/NPC1L1)		$\hat{\theta} = -0.38 [-0.42 - 0.35]; I^2 = 29\%$
Omitting A to Z (Simvastatin, HMGCR)		$\hat{\theta} = -0.38 [-0.42 - 0.35]; I^2 = 28\%$
Omitting SPIRE 1 & 2 (Bococizumab, PCSK9)		$\hat{\theta}_{+} = -0.38 [-0.420.35]; I^2 = 27\%$
Omitting REAL-CAD (Pitavastatin, HMGCR)		$\hat{\theta}_{+} = -0.38 \left[-0.420.35 \right]; I^2 = 28\%$
Omitting SHARP (Simvastatin/Ezetimibe, HMGCR/NPC1L1)		$\hat{\theta}_{*} = -0.38 \left[-0.420.35 \right]; I^{2} = 29\%$
Omitting REPRIEVE (Pitavastatin, HMGCR)		$\hat{\theta}_{*} = -0.38 [-0.420.35]; I^{2} = 28\%$
Omitting ALLIANCE (Atorvastatin, HMGCR)		$\hat{\theta}_{*} = -0.38 \left[-0.420.35 \right]; I^{2} = 28\%$
Omitting LIPS (Fluvastatin, HMGCR)		$\hat{\theta} = -0.38 [-0.42 - 0.35]; I^2 = 29\%$
Omitting PROSPER (Pravastatin, HMGCR)		$\hat{\theta} = -0.38 \left[-0.420.35 \right]; l^2 = 29\%$
Omitting ASCOT–LLA (Atorvastatin, HMGCR)		$\hat{\theta}_{*} = -0.38 [-0.420.35]; I^{2} = 29\%$
Omitting CARDS (Atorvastatin, HMGCR)		$\hat{\theta} = -0.38 [-0.42 - 0.35]; I^2 = 28\%$
Omitting LIPID (Pravastatin, HMGCR)		$\hat{\theta} = -0.38 [-0.42 - 0.34]; l^2 = 29\%$
Omitting SPARCL (Atorvastatin, HMGCR)		$\hat{\theta} = -0.38 [-0.42 - 0.34]; I^2 = 29\%$
Omitting MEGA (Pravastatin, HMGCR)		$\hat{\theta}_{*} = -0.38 [-0.420.34]; I^{2} = 26\%$
Omitting ODYSSEY OUTCOMES (Alirocumab, PCSK9)		$\hat{\theta}_{*} = -0.38 [-0.420.34]; I^{2} = 29\%$
Omitting PROVE-IT (Atorvastatin, HMGCR)		$\hat{\theta}_{*} = -0.38 [-0.420.34]; l^2 = 25\%$
Omitting CARE (Pravastatin, HMGCR)		$\hat{\theta}_{*} = -0.38 \left[-0.420.34 \right]; I^{2} = 28\%$
Omitting HOPE 3 (Rosuvastatin, HMGCR)		$\hat{\theta}_{*} = -0.38 \left[-0.420.34 \right]; I^{2} = 28\%$
Omitting FOURIER (Evolucumab, PCSK9)		$\hat{\theta}_{-} = -0.38 [-0.420.34]; I^2 = 28\%$
Omitting WOSCOPS (Pravastatin, HMGCR)		$\hat{\theta}_{*} = -0.38 \left[-0.420.34 \right]; I^{2} = 27\%$
Omitting JUPITER (Rosuvastatin, HMGCR)		$\hat{\theta}_{*} = -0.38 [-0.41 - 0.34]; I^{2} = 12\%$
Omitting IDEAL (Atorvastatin, HMGCR)		$\hat{\theta} = -0.38 [-0.41 - 0.34], I^2 = 26\%$
Omitting TNT (Atorvastatin, HMGCR)		$\hat{\theta} = -0.38 [-0.41 - 0.34], I^2 = 21\%$
Omitting HPS (Simvastatin, HMGCR)		$\hat{\theta}_{\tau} = -0.37 [-0.400.33], I^2 = 19\%$
	-0.5 -0.4 -0.3	-0.2 -0.1
	Effect Size (Fixed–Eff	ect Model)

Leave-one-out effect size sensitivity analysis of CETP inhibition



Sorted by Effect Size

(SUPPLEMENTAL FIGURE 6)

Comparison of ASCVD Risk and Cumulative LDL-C Exposure: CETP Inhibition vs. Guideline-Recommended Lipid-Lowering Therapies and LDLR PTVs



(SUPPLEMENTAL FIGURE 7)

Effect size & Heterogeneity

Leave-one-out effect size sensitivity analysis of statins, ezetimibe, PCSK9 inhibition, and LDLR PTVs



Sorted by Effect Size

Leave-one-out effect size sensitivity analysis of CETP inhibition



(SUPPLEMENTAL FIGURE 8)

Effect size & Heterogeneity

Leave-one-out effect size sensitivity analysis of statins, ezetimibe, PCSK9 inhibition, and LDLR PTVs



Leave-one-out effect size sensitivity analysis of CETP inhibition



Sorted by Effect Size

(SUPPLEMENTAL FIGURE 9)

A. Meta-Regression Without Interaction Term

(Formula = Atherosclerotic Disease Risk Reduction ~ LDL-C Reduction + Time of Follow-up)



B. Meta-Regression With Interaction Term

(Formula = Atherosclerotic Disease Risk Reduction ~ LDL-C Reduction + Time of Follow-up + LDL-C Reduction × Time of Follow-up)



LDL-C Reduction × Time of Follow-up (mmol/L × years)



(SUPPLEMENTAL FIGURE 10)

A. Meta-Regression Table of Adjusted Models

SUPPLEMENTAL FIGURE 10. Meta-Regression Sensitivity Analysis						
Model	Independent variables	β _{LDL-C} × Follow-Up	SE _{LDL-C ×} Follow-Up	P value	P value (Permutation)	
1	LDL-C Reduction, Time of Follow-Up, LDL-C Reduction × Time of Follow-Up	-0.0378	0.0131	0.0074	0.0090	
2	1 + Baseline LDL-C	-0.0343	0.0131	0.0136	0.0180	
3	1 + Annualized ASCVD event risk	-0.0384	0.0161	0.0236	0.0290	
4	1 + Cumulative ASCVD event risk	-0.0361	0.0133	0.0113	0.0110	
5	1 + Mean Age at Baseline	-0.0327	0.0128	0.0164	0.0250	
6	1 + Year published	-0.0356	0.0125	0.0079	0.0060	

B. Multi-Model Inference Analysis

